drug
lumasiran
Marketedupdated 5mo agoby $ALNY ALNYLAM PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying lumasiran
- phase3A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
- phase3A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
- phase2Lumasiran in Hyperoxalaemic Patients on Haemodialysis
- phase3A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
- phase2A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
- phase2An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
- —Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 23, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Nov 20, 2038compositionUS 11261447
- Oct 9, 2035compositionUS 10478500
- Oct 9, 2035compositionUS 11446380
- Aug 14, 2035compositionUS 10612024
- Aug 14, 2035compositionUS 10612027
- Aug 14, 2035compositionUS 11401517
- Dec 26, 2034method-of-use (U-2995)US 10435692
- Dec 26, 2034compositionUS 10465195
- Dec 26, 2034compositionUS 10487330
- Dec 26, 2034compositionUS 11060093
- Dec 26, 2034compositionUS 9828606
- Dec 12, 2029compositionUS 81060223.2y
- Dec 4, 2028compositionUS 88289562.2y
- Aug 24, 2028compositionUS 101319071.9y
FDA exclusivities (2)
- Oct 6, 2029ODE-415Orphan Drug (7y)3.0y
- Nov 23, 2027ODE-339Orphan Drug (7y)1.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that